ReviewaBIOTECH2026
Transgene-free genome editing in plants.
Review in aBIOTECH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome-editing tools for the precise, efficient modification of DNA have led to groundbreaking advances in crop improvement and basic plant science research. However, conventional genome editing may result in the integration of unintended gene fragments into the host genome, along with off-target effects and the risk of genetic drift of resistance genes. By contrast, transgene-free genome editing represents a revolutionary breakthrough due to its ability to 1) achieve precise and stable genomic modifications while minimizing foreign DNA integration through DNA-free or transient delivery of CRISPR components; and 2) deliver ribonucleoprotein complexes (RNPs) or mRNA into the host. In this review, we discuss the core principles of transgene-free genome-editing technologies, including the direct delivery of RNPs, mRNA delivery systems, the precise substitution of single nucleotides using cytosine or adenine base editors (CBEs, ABEs), and the mechanisms behind multiple types of prime editing that use templates for reverse transcriptases. These techniques have driven the development of crops considered nongenetically modified, as they do not contain stably integrated foreign DNA. Finally, we discuss future prospects, including the development of transgene-free genome-editing tools that combine delivery systems with artificial intelligence-assisted optimization, with promising applications for agriculture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.